4 documents

Read All
22:06 , Apr 28, 2017 |  BioCentury  |  Emerging Company Profile

Cutting cravings

The former executive team from CV Therapeutics Inc. are treading familiar ground with an addiction program licensed from Gilead Sciences Inc. Newco Amygdala Neurosciences Inc. aims to develop ANS-6673 to treat substance abuse disorders currently...
Read More
03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc.’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research plan...
Read More
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Cannabidiol: Phase II started

Insys said investigators began a double-blind, placebo-controlled, Canadian Phase II trial to evaluate 400 mg oral CBD for 2 days followed by 800 mg CBD for 92 days in about 110 cocaine-dependent patients. Patients who...
Read More
07:00 , May 25, 2015 |  BC Week In Review  |  Clinical News

Cannabidiol: Phase I/II started

Insys began an open-label, U.S. Phase I/II trial to evaluate 3 multiple ascending doses of CBD oral solution in about 60 patients ages 1-17. Insys Therapeutics Inc. (NASDAQ:INSY), Phoenix, Ariz.   Product: Cannabidiol (CBD) oral...
Read More